ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
US Tech 100
17,244.80
1.57%
Dow Jones
38,239.66
0.40%
Brent Oil
88.165
0.00%
Bitcoin
63,094.30
-1.01%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Revolution Medicines Inc (RVMD) Quote

Revolution Medicines Inc

Revolution Medicines Inc (RVMD)

NASDAQ
35.96
0.63
(1.78%)
Closed April 27 4:00PM
Delayed by 15 minutes
36.05
0.09
(0.25%)
After Hours: 5:49PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
36.05
Bid
36.05
Ask
39.00
Volume
1,213,741
34.65 Day's Range 36.36
15.4401 52 Week Range 38.73
Market Cap
57.642M
Previous Close
35.33
Open
35.38
Last Trade
397
@
36.05
(formt)
Last Trade Time
Financial Volume
$ 43,348,294
VWAP
35.7146
Average Volume (3m)
1,513,076
Shares Outstanding
164,690,408
Dividend Yield
-
PE Ratio
-0.13
Earnings Per Share (EPS)
-2.65
Revenue
11.58M
Net Profit
-436.37M

About Revolution Medicines Inc

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include R... Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.revmed.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Revolution Medicines Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker RVMD. The last closing price for Revolution Medicines was $35.33. Over the last year, Revolution Medicines shares have traded in a share price range of $ 15.4401 to $ 38.73.

Revolution Medicines currently has 164,690,408 shares outstanding. The market capitalization of Revolution Medicines is $57.64 million. Revolution Medicines has a price to earnings ratio (PE ratio) of -0.13.

Revolution Medicines (RVMD) Options Flow Summary

RVMD Options Flow

Overall Flow

Bearish

Net Premium

-9k

Calls / Puts

100.00%

Buys / Sells

0.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

RVMD Latest News

More News

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

April 09 2024
GlobeNewswire Inc.

Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in...

April 08 2024
GlobeNewswire Inc.

Revolution Medicines to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

April 04 2024
GlobeNewswire Inc.

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

March 28 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

March 05 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

March 05 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

March 05 2024
Edgar (US Regulatory)

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

March 04 2024
Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans

February 26 2024
Edgar (US Regulatory)

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

February 26 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.040.11108025548536.0137.8734.23120049435.68027326CS
43.9712.375311720732.0838.7329.55140331434.935129CS
128.1829.350556153627.8738.7327.46151307632.13207346CS
2615.7977.936821322820.2638.7318155314727.7792461CS
5213.0756.875543951322.9838.7315.4401155691227.42564049CS
156-5.88-14.023372287141.9343.4914.08105719025.78742001CS
2606.722.827938671229.3556.1814.0887512627.29163803CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BDRXBiodexa Pharmaceuticals PLC
$ 1.3254
(82.86%)
70.82M
IBRXImmunityBio Inc
$ 7.35
(43.84%)
40.28M
AGENAgenus Inc
$ 11.685
(40.78%)
3.37M
ULHUniversal Logistics Holdings Inc
$ 45.63
(38.74%)
484.22k
NIVFNewGenIvf Group Ltd
$ 1.77
(36.15%)
57.78M
MFImF International Ltd
$ 2.3153
(-77.82%)
21.23M
NWGLNature Wood Group Ltd
$ 5.05
(-70.03%)
2.48M
ICLKiClick Interactive Asia Group Ltd
$ 1.21
(-52.17%)
719.95k
NUWENewellis Inc
$ 0.1695
(-41.35%)
18.46M
SGBXSafe and Green Holdings Corporation
$ 0.1469
(-32.92%)
8.39M
PEGYPineapple Energy Inc
$ 0.065499
(26.20%)
325.57M
SQQQProShares UltraPro Short QQQ
$ 11.43
(-4.75%)
137.28M
INTCIntel Corporation
$ 31.88
(-9.20%)
119.84M
TSLATesla Inc
$ 168.29
(-1.11%)
109.84M
SOFISoFi Technologies Inc
$ 7.87
(3.69%)
88.63M

RVMD Discussion

View Posts
axelvento axelvento 3 weeks ago
Dr Olive added: 'I’ve been working on pancreatic cancer for almost 20 years, and I’ve never seen preclinical results like these.

'I think there is a real chance this approach will help change the standard of care for pancreatic cancer patients, but only clinical trials can determine that
👍️0
axelvento axelvento 3 weeks ago
Breakthrough in fight against world's deadliest cancer - new drug shrunk up to 70% of pancreatic tumors in lab study

https://www.dailymail.co.uk/health/article-13284461/pancreatic-cancer-breakthrough-deadliest-disease-study.html
👍️0
Monksdream Monksdream 3 weeks ago
RVMD over $30
👍️0
Monksdream Monksdream 2 months ago
RVMD 10Q. 2/26
👍️0

Your Recent History

NASDAQ
RVMD
Revolution Medicines
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved